dc.contributor.authors |
Aras, YG; Tanik, O; Gungen, BD; Kotan, D; |
|
dc.date.accessioned |
2020-02-27T08:51:51Z |
|
dc.date.available |
2020-02-27T08:51:51Z |
|
dc.date.issued |
2016 |
|
dc.identifier.citation |
Aras, YG; Tanik, O; Gungen, BD; Kotan, D; (2016). PATIENT CHARACTERISTICS AND THE EFFECTS OF INTRAVENOUS IMMUNOGLOBULIN IN PATIENTS WITH GUILLAIN-BARRE SYNDROME. IDEGGYOGYASZATI SZEMLE-CLINICAL NEUROSCIENCE, 69, 395-389 |
|
dc.identifier.issn |
0019-1442 |
|
dc.identifier.uri |
https://doi.org/10.18071/isz.69.0389 |
|
dc.identifier.uri |
https://hdl.handle.net/20.500.12619/67029 |
|
dc.description.abstract |
Conclusion - In this study, demyelinating form was more frequent than axonal form. A total of 2 g/kg dose of IVIg treatment administered for 5 days as a standard in GBS patients ensured a significant improvement on both disability and early and late administration and early administration of the treatment does not lead to any difference in intensive care unit and rehabilitation requirements. |
|
dc.language |
English |
|
dc.publisher |
LITERATURA MEDICA |
|
dc.subject |
Neurosciences & Neurology |
|
dc.title |
PATIENT CHARACTERISTICS AND THE EFFECTS OF INTRAVENOUS IMMUNOGLOBULIN IN PATIENTS WITH GUILLAIN-BARRE SYNDROME |
|
dc.type |
Article |
|
dc.identifier.volume |
69 |
|
dc.identifier.startpage |
389 |
|
dc.identifier.endpage |
395 |
|
dc.contributor.department |
Sakarya Üniversitesi/Tıp Fakültesi/Dahili Tıp Bilimleri Bölümü |
|
dc.contributor.saüauthor |
Güzey Aras, Yeşim |
|
dc.contributor.saüauthor |
Kotan Dündar, Dilcan |
|
dc.relation.journal |
IDEGGYOGYASZATI SZEMLE-CLINICAL NEUROSCIENCE |
|
dc.identifier.wos |
WOS:000391162900004 |
|
dc.identifier.doi |
10.18071/isz.69.0389 |
|
dc.contributor.author |
Güzey Aras, Yeşim |
|
dc.contributor.author |
Osman Tanik |
|
dc.contributor.author |
Belma Dogan Gungen |
|
dc.contributor.author |
Kotan Dündar, Dilcan |
|